BPG is committed to discovery and dissemination of knowledge
Randomized Controlled Trial
©The Author(s) 2025.
World J Gastroenterol. Dec 21, 2025; 31(47): 114377
Published online Dec 21, 2025. doi: 10.3748/wjg.v31.i47.114377
Table 5 Age-stratified analysis of eradication efficacy, adherence, and adverse events across the three vonoprazan-amoxicillin regimens, n (%)
Regimen
Age group
n (ITT)
Eradicated
Adherence ≥ 80%
Adverse events
P value (by age)
0.5 g-QID18-39205194 (94.6)200 (97.6)6 (2.9)< 0.05
40-59285270 (94.7)281 (98.6)21 (7.4)< 0.05
60-707866 (84.6)77 (98.7)4 (5.1)< 0.05
0.75 g-QID18-39188179 (95.2)181 (96.3)19 (10.1)< 0.05
40-59282273 (96.8)279 (98.9)7 (2.5)< 0.05
60-7010485 (81.7)103 (99.0)4 (3.8)< 0.05
1 g-TID18-39234214 (91.5)228 (97.4)14 (6.0)> 0.05
40-59281265 (94.3)277 (98.6)28 (10.0)> 0.05
60-706052 (86.7)60 (100.0)1 (1.7)> 0.05


Write to the Help Desk